Both management and prognosis vary with the many different varieties of non-Hodgkin's lymphoma. In large-cell disease, age and other risk factors influence prognosis. Relapses may respond to chemotherapy plus autologous bone marrow transplantation. Therapy with antibodies to tumor cells has made its debut, but its role remains unclear.
|Original language||English (US)|
|Number of pages||8|
|State||Published - Dec 15 1999|
ASJC Scopus subject areas